Open AccessComparative Investigation of Spot Kit Versus RTPCR in COVID Active Patients
Author(s) -
Lavanya Sehrawat,
Kishor Hiwale
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i60b34646
Subject(s) - covid-19 , pandemic , coronavirus , medicine , virology , pneumonia , disease , biology , outbreak , infectious disease (medical specialty)
On 31 December 2019, numerous pneumonitis occurrences of pneumonitis of uncertain origin, in Wuhan city, People’s Republic of China. The previously unknown origin was identified and designated the 2019 new Coronavirus in January 2020. WHO eventually dubbed it Coronavirus disease 2019 (COVID-19). The infection has been identified as Coronavirus-2, which causes severe acute respiratory illness (SARS-CoV-2). It was crucial to control the rapid evolving SARS-CoV-2-associated Coronavirus disease 2019 pandemic. In order to do so, highly sensitive and specific lab diagnostic assessments like RTPCR and Genome sequencing helped in identifying the cases at an early stage which further helped increasing the rate of survival. With time multiple tests were formulated which aided us but a need for the best and more accurate one was still needed. Some of these tests were quick but had a lower level efficacy while the old tests were accurate but are really slow. In this review article, we have formulated a comparative investigation of spot kit versus RTPCR in COVID active Patients from case reports, original investigation articles published by PubMed and Google scholar. With the help of these articles we have come a the best possible conclusion. The conclusion came out as COVID-19 patients found positive by RTPCR but negative by spot kit are uncommon to be infectious.